DK3003038T3 - 2h-1,2,3-triazolderivater som inhibitorer af fibrose - Google Patents
2h-1,2,3-triazolderivater som inhibitorer af fibrose Download PDFInfo
- Publication number
- DK3003038T3 DK3003038T3 DK14807059T DK14807059T DK3003038T3 DK 3003038 T3 DK3003038 T3 DK 3003038T3 DK 14807059 T DK14807059 T DK 14807059T DK 14807059 T DK14807059 T DK 14807059T DK 3003038 T3 DK3003038 T3 DK 3003038T3
- Authority
- DK
- Denmark
- Prior art keywords
- fibrose
- inhibitors
- triazold
- derivatives
- triazold derivatives
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 0 CCC(C)NI(=C)=C*Cc(nc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(c(ccc(C2CC2)c2)c2Cl)OC1 Chemical compound CCC(C)NI(=C)=C*Cc(nc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(c(ccc(C2CC2)c2)c2Cl)OC1 0.000 description 12
- CSWWLZIHWDOBBW-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC(CC1)COC1(C[n]1nccn1)c1cc(Cl)ccc1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC(CC1)COC1(C[n]1nccn1)c1cc(Cl)ccc1 CSWWLZIHWDOBBW-UHFFFAOYSA-N 0.000 description 1
- IGTXBBCIJVOAHQ-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CN2N=CC=C=CC2)(C(C)C)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CN2N=CC=C=CC2)(C(C)C)OC1 IGTXBBCIJVOAHQ-UHFFFAOYSA-N 0.000 description 1
- JLJRJROYXTUSTB-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CC2)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CC2)OC1 JLJRJROYXTUSTB-UHFFFAOYSA-N 0.000 description 1
- MVCZVFITFGIFLB-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCC2)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCC2)OC1 MVCZVFITFGIFLB-UHFFFAOYSA-N 0.000 description 1
- WPLVDSGIYZTOAR-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCNCC2)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCNCC2)OC1 WPLVDSGIYZTOAR-UHFFFAOYSA-N 0.000 description 1
- HHPHXSRMJRFBSK-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCOCC2)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCOCC2)OC1 HHPHXSRMJRFBSK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Agronomy & Crop Science (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832768P | 2013-06-07 | 2013-06-07 | |
| PCT/US2014/041174 WO2014197738A1 (en) | 2013-06-07 | 2014-06-05 | Small molecule inhibitors of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3003038T3 true DK3003038T3 (da) | 2019-11-11 |
Family
ID=52008597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14807059T DK3003038T3 (da) | 2013-06-07 | 2014-06-05 | 2h-1,2,3-triazolderivater som inhibitorer af fibrose |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9663499B2 (https=) |
| EP (2) | EP3626242B1 (https=) |
| JP (1) | JP6414831B2 (https=) |
| KR (1) | KR102240329B1 (https=) |
| CN (1) | CN105392364B (https=) |
| AU (1) | AU2014274830B2 (https=) |
| BR (1) | BR112015030203A2 (https=) |
| CA (1) | CA2913634C (https=) |
| CL (1) | CL2015003569A1 (https=) |
| DK (1) | DK3003038T3 (https=) |
| EA (1) | EA201592157A1 (https=) |
| ES (2) | ES2755125T3 (https=) |
| HK (1) | HK1221606A1 (https=) |
| MX (1) | MX2015016783A (https=) |
| PE (1) | PE20160523A1 (https=) |
| PL (1) | PL3003038T3 (https=) |
| PT (1) | PT3003038T (https=) |
| SG (1) | SG11201510011VA (https=) |
| TN (1) | TN2015000519A1 (https=) |
| WO (1) | WO2014197738A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| EP3318255B1 (en) | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| EP3626242B1 (en) | 2013-06-07 | 2024-08-07 | The Scripps Research Institute | Itraconazole analogs as inhibitors of fibrosis |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| JP6706023B2 (ja) * | 2014-12-10 | 2020-06-03 | ザ・スクリップス・リサーチ・インスティテュート | 線維症の小分子阻害剤 |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| WO2017184586A1 (en) * | 2016-04-18 | 2017-10-26 | The Trustees Of Columbia University In The City Of New York | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash) |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN106866459A (zh) * | 2017-03-30 | 2017-06-20 | 成都绿林科技有限公司 | 一种抗真菌药物中间体的制备方法 |
| CN106986787A (zh) * | 2017-03-30 | 2017-07-28 | 成都绿林科技有限公司 | 一种泊沙康唑中间体的合成方法 |
| WO2019183006A1 (en) | 2018-03-19 | 2019-09-26 | Liang Gui Bai | Methods and compositions for treating idiopathic pulmonary fibrosis |
| LT3750536T (lt) | 2018-09-24 | 2026-03-25 | Amarin Pharmaceuticals Ireland Limited | Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai |
| EP3863723A4 (en) * | 2018-10-14 | 2022-09-07 | The University of Chicago | Compositions and methods for activating nrf2-dependent gene expression |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| EP4132531A4 (en) * | 2020-04-07 | 2024-04-17 | Amarin Pharmaceuticals Ireland Limited | METHODS OF TREATING AND/OR PREVENTING VIRAL INFECTIONS AND/OR DISEASES CAUSED BY VIRUSES IN A SUBJECT IN NEED THEREOF |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| US4791111A (en) | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
| IL103558A0 (en) * | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
| CN1041425C (zh) | 1993-11-19 | 1998-12-30 | 国际壳牌研究有限公司 | 氧化稳定的聚酮聚合物组合物及其应用 |
| US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
| US5625064A (en) * | 1995-04-19 | 1997-04-29 | Schering Corporation | Process for the preparation of triazolones |
| TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
| EP0957101A1 (en) | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| JP2004501147A (ja) | 2000-06-20 | 2004-01-15 | アセロジエニクス・インコーポレイテツド | １，３−ビス−（置換フェニル）−２−プロペン−１−オン類およびｖｃａｍ−１媒介障害を治療するためのそれらの使用 |
| EP1511490A4 (en) * | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| CA2709203A1 (en) | 2007-12-13 | 2009-06-18 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| WO2010021681A2 (en) | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20110183948A1 (en) | 2010-01-15 | 2011-07-28 | Infinity Pharmaceuticals, Inc. | Treatment of fibrotic conditions using hedgehog inhibitors |
| GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| WO2012047762A2 (en) | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
| EP3360552A1 (en) | 2010-12-07 | 2018-08-15 | Amira Pharmaceuticals, Inc. | Polycyclic lpa1 antagonist and uses thereof |
| US9346791B2 (en) * | 2011-09-07 | 2016-05-24 | The Johns Hopkins University | Itraconazole analogs and use thereof |
| US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
| US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| WO2014195888A1 (en) | 2013-06-07 | 2014-12-11 | Rhizen Pharmaceuticals Sa | Dual selective pi3 delta and gamma kinase inhibitors |
| EP3626242B1 (en) | 2013-06-07 | 2024-08-07 | The Scripps Research Institute | Itraconazole analogs as inhibitors of fibrosis |
-
2014
- 2014-06-05 EP EP19191562.8A patent/EP3626242B1/en active Active
- 2014-06-05 DK DK14807059T patent/DK3003038T3/da active
- 2014-06-05 ES ES14807059T patent/ES2755125T3/es active Active
- 2014-06-05 CN CN201480032411.7A patent/CN105392364B/zh active Active
- 2014-06-05 BR BR112015030203A patent/BR112015030203A2/pt not_active IP Right Cessation
- 2014-06-05 TN TN2015000519A patent/TN2015000519A1/en unknown
- 2014-06-05 PT PT148070592T patent/PT3003038T/pt unknown
- 2014-06-05 WO PCT/US2014/041174 patent/WO2014197738A1/en not_active Ceased
- 2014-06-05 PE PE2015002576A patent/PE20160523A1/es not_active Application Discontinuation
- 2014-06-05 HK HK16109962.7A patent/HK1221606A1/zh unknown
- 2014-06-05 CA CA2913634A patent/CA2913634C/en active Active
- 2014-06-05 US US14/895,813 patent/US9663499B2/en active Active
- 2014-06-05 MX MX2015016783A patent/MX2015016783A/es unknown
- 2014-06-05 JP JP2016518012A patent/JP6414831B2/ja active Active
- 2014-06-05 EP EP14807059.2A patent/EP3003038B1/en active Active
- 2014-06-05 ES ES19191562T patent/ES2991873T3/es active Active
- 2014-06-05 PL PL14807059T patent/PL3003038T3/pl unknown
- 2014-06-05 KR KR1020157036822A patent/KR102240329B1/ko active Active
- 2014-06-05 SG SG11201510011VA patent/SG11201510011VA/en unknown
- 2014-06-05 AU AU2014274830A patent/AU2014274830B2/en active Active
- 2014-06-05 EA EA201592157A patent/EA201592157A1/ru unknown
-
2015
- 2015-12-07 CL CL2015003569A patent/CL2015003569A1/es unknown
-
2017
- 2017-04-14 US US15/488,206 patent/US9981956B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1221606A1 (zh) | 2017-06-09 |
| US20170217943A1 (en) | 2017-08-03 |
| BR112015030203A2 (pt) | 2017-07-25 |
| EP3626242B1 (en) | 2024-08-07 |
| US9981956B2 (en) | 2018-05-29 |
| CN105392364B (zh) | 2018-09-14 |
| EA201592157A1 (ru) | 2016-05-31 |
| EP3003038A4 (en) | 2016-11-16 |
| AU2014274830B2 (en) | 2017-11-09 |
| CL2015003569A1 (es) | 2016-11-11 |
| CN105392364A (zh) | 2016-03-09 |
| CA2913634A1 (en) | 2014-12-11 |
| PT3003038T (pt) | 2019-11-19 |
| JP6414831B2 (ja) | 2018-10-31 |
| AU2014274830A1 (en) | 2015-11-26 |
| PL3003038T3 (pl) | 2020-02-28 |
| ES2991873T3 (es) | 2024-12-05 |
| US9663499B2 (en) | 2017-05-30 |
| MX2015016783A (es) | 2016-07-18 |
| KR102240329B1 (ko) | 2021-04-14 |
| JP2016521710A (ja) | 2016-07-25 |
| US20160130258A1 (en) | 2016-05-12 |
| WO2014197738A1 (en) | 2014-12-11 |
| TN2015000519A1 (en) | 2017-04-06 |
| EP3003038B1 (en) | 2019-08-14 |
| EP3003038A1 (en) | 2016-04-13 |
| EP3626242A1 (en) | 2020-03-25 |
| CA2913634C (en) | 2022-08-09 |
| PE20160523A1 (es) | 2016-05-25 |
| ES2755125T3 (es) | 2020-04-21 |
| SG11201510011VA (en) | 2016-01-28 |
| KR20160029028A (ko) | 2016-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3003038T3 (da) | 2h-1,2,3-triazolderivater som inhibitorer af fibrose | |
| DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
| DK3527263T3 (da) | Bipyrazolderivater som jak-inhibitorer | |
| DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
| IL245672B (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| DK3071203T3 (da) | Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer | |
| HUE058009T2 (hu) | 1,3-Tiazol-2-il szubsztituált benzamid-származékok | |
| DK3077374T3 (da) | Pyrrolidinoner som herbicider | |
| LT3022217T (lt) | Kompozicijos, skirtos tau ekspresijos moduliavimui | |
| DK3019496T3 (da) | Pyrimidinderivater som kinaseinhibitorer | |
| LT3689865T (lt) | Nauji aminopirimidinų dariniai | |
| DK3342771T3 (da) | Heterocykliske amider som kinaseinhibitorer | |
| DK3066085T3 (da) | Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor | |
| DK2986726T3 (da) | Hidtil ukendte bacillusstammesammensætninger | |
| LT3609898T (lt) | Junginiai, naudingi kaip ret inhibitoriai | |
| DK3357919T3 (da) | Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser | |
| DK3094631T4 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
| DK3466949T3 (da) | Tricyklisk forbindelse som anticancermidler | |
| DK2981535T3 (da) | Urinstofderivater, der er anvendelige som kinaseinhibitorer | |
| DK3054936T5 (da) | 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer | |
| DK3313832T3 (da) | 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere | |
| DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
| DK3013796T3 (da) | Biarylderivater som gpr120-agonister | |
| DK2975030T3 (da) | Dihydropyridazin-3,5-dion-derivat | |
| PL2945641T3 (pl) | Cykloalkinowe pochodne sacharydów |